Literature DB >> 11907247

Preferential localization of the Epstein-Barr virus (EBV) oncoprotein LMP-1 to nuclei in human T cells: implications for its role in the development of EBV genome-positive T-cell lymphomas.

Jingwu Xu1, Ali Ahmad, José Menezes.   

Abstract

The Epstein-Barr virus (EBV)-encoded latent membrane protein-1 (LMP-1) is thought to play a role in the EBV-induced B-cell transformation and immortalization. EBV has also been implicated in certain human T-cell lymphomas; however, the phenotypic effects of the expression of this oncoprotein in T cells are not known. To learn whether LMP-1 also induces phenotypic changes in T cells, we stably expressed it in human cell lines of T and B lineages and 25 LMP-1-expressing T-cell clones and 7 B-cell clones were examined. Our results show for the first time that, in sharp contrast to B cells, LMP-1 preferentially localizes to nuclei in T cells and does not induce the phenotypic changes in these cells that it induces in B cells, does not associate with TRAF proteins, and does not arrest the cell cycle in the G2/M phase. A computer-assisted analysis revealed that LMP-1 lacks the canonical nuclear localization signal. Our results suggest that this oncoprotein may not play the same role in the lymphomagenesis of T cells as it does in B cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11907247      PMCID: PMC136072          DOI: 10.1128/jvi.76.8.4080-4086.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  52 in total

1.  Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma.

Authors:  Y Harabuchi; N Yamanaka; A Kataura; S Imai; T Kinoshita; F Mizuno; T Osato
Journal:  Lancet       Date:  1990-01-20       Impact factor: 79.321

2.  Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation.

Authors:  C W Dawson; A B Rickinson; L S Young
Journal:  Nature       Date:  1990-04-19       Impact factor: 49.962

Review 3.  Nucleocytoplasmic transport: signals, mechanisms and regulation.

Authors:  E A Nigg
Journal:  Nature       Date:  1997-04-24       Impact factor: 49.962

4.  Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.

Authors:  F Wang; C Gregory; C Sample; M Rowe; D Liebowitz; R Murray; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

5.  Severe chronic EBV infection associated with specific EBV immunodeficiency and an EBNA+ T-cell lymphoma containing linear, EBV DNA.

Authors:  V R Bonagura; B Z Katz; B L Edwards; D J Valacer; P Nisen; E Gloster; R Mir; P Lanzkowsky
Journal:  Clin Immunol Immunopathol       Date:  1990-10

6.  Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene.

Authors:  K L Fries; W E Miller; N Raab-Traub
Journal:  J Virol       Date:  1996-12       Impact factor: 5.103

7.  Expression of Epstein-Barr virus latent membrane protein 1 protects Jurkat T cells from apoptosis induced by serum deprivation.

Authors:  M Kawanishi
Journal:  Virology       Date:  1997-02-17       Impact factor: 3.616

8.  Epstein-Barr virus latent infection membrane protein increases vimentin expression in human B-cell lines.

Authors:  M Birkenbach; D Liebowitz; F Wang; J Sample; E Kieff
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

9.  Epstein-Barr virus latent membrane protein: induction of B-cell activation antigens and membrane patch formation does not require vimentin.

Authors:  D Liebowitz; E Kieff
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

10.  Infection of human thymocytes by Epstein-Barr virus.

Authors:  D Watry; J A Hedrick; S Siervo; G Rhodes; J J Lamberti; J D Lambris; C D Tsoukas
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

View more
  5 in total

1.  Epstein-Barr virus positive anaplastic large cell lymphoma: myth or reality?

Authors:  Ly Ma; Youval Katz; Kanu P Sharan; Roland Schwarting; Annette S Kim
Journal:  Int J Clin Exp Pathol       Date:  2010-11-20

Review 2.  Diagnosis and treatment of Epstein-Barr virus-associated natural killer cell lymphoproliferative disease.

Authors:  Keisei Kawa
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

3.  The Epstein-Barr virus LMP1 interactome: biological implications and therapeutic targets.

Authors:  Mujeeb R Cheerathodi; David G Meckes
Journal:  Future Virol       Date:  2018-12-03       Impact factor: 1.831

4.  Repression of Hox genes by LMP1 in nasopharyngeal carcinoma and modulation of glycolytic pathway genes by HoxC8.

Authors:  Y Jiang; B Yan; W Lai; Y Shi; D Xiao; J Jia; S Liu; H Li; J Lu; Z Li; L Chen; X Chen; L Sun; K Muegge; Y Cao; Y Tao
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

Review 5.  New Insights from Elucidating the Role of LMP1 in Nasopharyngeal Carcinoma.

Authors:  Kathy H Y Shair; Akhil Reddy; Vaughn S Cooper
Journal:  Cancers (Basel)       Date:  2018-03-21       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.